The Centers for Medicare & Medicaid Services has issued a permanent billing and reimbursement J-code, J9183, for the ...
The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
UGN-102 shows a 79.6% complete response rate in recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer. UGN-102 offers a non-surgical alternative, avoiding cystoscopy and anesthesia, ...
Immunotherapy uses the power of your immune system to fight your cancer. One type of immunotherapy is called an immune checkpoint inhibitor. Your immune system has built-in checkpoints that help it ...
Immunocompromised patients with bladder had a higher risk of disease progression and recurrence when compared to their non-immunocompromised counterparts. Immunocompromised patients with bladder ...
Relmada Therapeutics announced a licensing agreement for NDV-01, a new treatment for non-muscle invasive bladder cancer. Phase 2 data expected in April 2025. Relmada Therapeutics, Inc. has announced ...
NMIBC treatment varies by tumor stage, grade, and prior therapies, with high-risk cases often requiring radical cystectomy. Bladder-preserving approaches include intravesical therapies like BCG, ...
Advances in Bladder Cancer: innovation in diagnostics, therapeutic technology, and clinical pathways
Non–muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) continue to pose significant clinical and health-economic challenges in ...
This week in oncology, the FDA expanded the treatment landscape for platinum-resistant ovarian cancer with a new approval, and significant clinical data emerged regarding novel in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results